DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Small Study / Early Comparative Evidence
DCCBs are routinely added as second- or third-line antihypertensive therapy in type 2 diabetes when RASi and SGLT2i fail to achieve blood pressure targets. This retrospective cohort of 31,041 adults raises a signal that DCCB use may accelerate diabetic kidney disease progression in patients already on modern kidney-protective regimens.
Clinical Considerations
- DCCB use was associated with 33% higher risk of major adverse kidney events versus non-DCCB antihypertensives over a median 3.5-year follow-up
- Residual confounding and indication bias cannot be excluded; findings have not yet appeared in a peer-reviewed journal
- A 2022 study of nearly 10,000 patients suggested DCCBs may reduce advanced CKD risk, placing these new findings in direct conflict with prior data
- Thiazide diuretics are proposed as an alternative add-on option, though they require monitoring of GFR and serum electrolytes
Practice Applications
- Recognize this as an early signal warranting attention, not a basis for changing prescribing patterns pending peer review and replication
- Consider thiazide diuretics as an alternative add-on in type 2 diabetes patients requiring third-line antihypertensive therapy
- Monitor GFR and electrolytes closely when initiating thiazide therapy in this population
- Interpret kidney outcomes data in diabetic hypertension patients with awareness of ongoing uncertainty around DCCB risk
